At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 222 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
In Brief
A Phase 2 clinical trial evaluating adalimumab and ABT-122 for Rheumatoid Arthritis. Completed, enrolled 222 participants.
Detailed Summary
This study is a Phase 2 randomized, double-blind, double-dummy, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of ABT 122 in subjects with active rheumatoid arthritis (RA) who are inadequately responding to methotrexate (MTX) treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJul 2014
Primary CompletionSep 2015
Study CompletionNov 2015
TodayJul 2026
First PostedMay 20, 2014
Enrollment StartJul 1, 2014
Primary CompletionSep 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.1 years ago
Interventions
adalimumabbiological
adalimumab administered as subcutaneous injection every other week (EOW)
ABT-122biological
ABT-122 administered as subcutaneous injection every other week (EOW)